{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:03:30Z","timestamp":1784124210121,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumour-infiltrating FOXP3\n                    <jats:sup>+<\/jats:sup>\n                    regulatory T cells (Tregs) exert suppression of anti-tumour immunity in non-small cell lung cancer (NSCLC), contributing to poor prognosis and immunotherapy resistance. The BCL-2 family pro-survival protein, MCL-1, is a critical controller of lymphoid Treg viability, yet its role in tumour-infiltrating Tregs remains poorly defined. Here we find that tumour-infiltrating effector Tregs in human NSCLC exhibit an activation-associated shift in BCL-2 family pro-survival protein expression typified by elevated MCL-1 expression. Pharmacological inhibition of MCL-1 with the BH3 mimetic S63845 induced moderate apoptotic cell death in both human and murine tumour-infiltrating Tregs, coincident with transient enhancement of CD8\u207a T cell activity. Combined MCL-1 inhibition and anti-PD1 immunotherapy further reduced tumour-infiltrating effector Treg abundance and influenced CD8\u207a T cell dynamics, although these effects were not sufficient to extend long-term survival. Mechanistically, we found that IL-33 upregulated MCL-1 expression and was required to support activated tumour-infiltrating Tregs. These results establish MCL-1 as an important regulator for tumour-infiltrating Treg survival and highlight the potential of repurposing BH3 mimetics to modulate immune suppression in NSCLC.\n                  <\/jats:p>","DOI":"10.1038\/s41418-026-01820-8","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:12:29Z","timestamp":1784117549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer"],"prefix":"10.1038","author":[{"given":"Eddy","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare E.","family":"Weeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-8772","authenticated-orcid":false,"given":"Claire","family":"Marceaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-1569","authenticated-orcid":false,"given":"Lucille","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Batey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9745-2876","authenticated-orcid":false,"given":"Charis E.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-8242","authenticated-orcid":false,"given":"Daniel HD","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-6076","authenticated-orcid":false,"given":"Marie-Liesse","family":"Asselin-Labat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1820_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA A Cancer J Clin"},{"key":"1820_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jtho.2024.09.1439","volume":"20","author":"S Peters","year":"2025","unstructured":"Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, et al. Long-term survival outcomes with first-line nivolumab plus ipilimumab\u2013based treatment in patients with metastatic NSCLC and tumor programmed death-ligand 1 lower than 1%: a pooled analysis. J Thorac Oncol. 2025;20:94\u2013108.","journal-title":"J Thorac Oncol"},{"key":"1820_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Immunology. 2012;30:531\u201364.","journal-title":"Immunology"},{"key":"1820_CR4","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1183\/13993003.00176-2014","volume":"46","author":"DS O\u2019Callaghan","year":"2015","unstructured":"O\u2019Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O\u2019Donnell DM, et al. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. Eur Respir J. 2015;46:1762\u201372.","journal-title":"Eur Respir J"},{"key":"1820_CR5","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-08-2360","volume":"69","author":"M Gobert","year":"2009","unstructured":"Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22\/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69:2000\u20139.","journal-title":"Cancer Res"},{"key":"1820_CR6","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.18632\/oncotarget.6958","volume":"7","author":"HS Choi","year":"2016","unstructured":"Choi HS, Ha SY, Kim H-M, Ahn SM, Kang M-S, Kim K-M, et al. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget. 2016;7:7940\u201351.","journal-title":"Oncotarget"},{"key":"1820_CR7","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","volume":"72","author":"A Facciabene","year":"2012","unstructured":"Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162\u201371.","journal-title":"Cancer Res"},{"key":"1820_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","volume":"43","author":"NS Joshi","year":"2015","unstructured":"Joshi NS, Akama-Garren EH, Lu Y, Lee D-Y, Chang GP, Li A, et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity. 2015;43:579\u201390.","journal-title":"Immunity"},{"key":"1820_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jtho.2025.02.029","volume":"20","author":"P Chen","year":"2025","unstructured":"Chen P, Wang H, Tang Z, Shi J, Cheng L, Zhao C, et al. Selective depletion of CCR8+Treg cells enhances the antitumor immunity of cytotoxic T cells in lung cancer by dendritic cells. J Thorac Oncol. 2025;20:1050\u201374.","journal-title":"J Thorac Oncol"},{"key":"1820_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09458-5","volume":"12","author":"M Haruna","year":"2022","unstructured":"Haruna M, Ueyama A, Yamamoto Y, Hirata M, Goto K, Yoshida H, et al. The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. Sci Rep. 2022;12:5377.","journal-title":"Sci Rep"},{"key":"1820_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1682380","volume":"9","author":"B-S Kim","year":"2020","unstructured":"Kim B-S, Clinton J, Wang Q, Chang SH. Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer. OncoImmunology. 2020;9:1682380.","journal-title":"OncoImmunology"},{"key":"1820_CR12","doi-asserted-by":"publisher","first-page":"e004605","DOI":"10.1136\/jitc-2022-004605","volume":"10","author":"D Noyes","year":"2022","unstructured":"Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, et al. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. J Immunother Cancer. 2022;10:e004605.","journal-title":"J Immunother Cancer"},{"key":"1820_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jaci.2009.02.011","volume":"123","author":"S L\u00e9tourneau","year":"2009","unstructured":"L\u00e9tourneau S, Krieg C, Pantaleo G, Boyman O. IL-2\u2013 and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009;123:758\u201362.","journal-title":"J Allergy Clin Immunol"},{"key":"1820_CR14","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.2025.43.16_suppl.4010","volume":"43","author":"J Gong","year":"2025","unstructured":"Gong J, Liu C, Liu L, Yao J, Mou Y, Dai J, et al. Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1\/2 studies. J Clin Oncol. 2025;43:4010\u20134010.","journal-title":"J Clin Oncol"},{"key":"1820_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nature02067","volume":"426","author":"JT Opferman","year":"2003","unstructured":"Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426:671\u20136.","journal-title":"Nature"},{"key":"1820_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.virol.2016.01.008","volume":"490","author":"EH Kim","year":"2016","unstructured":"Kim EH, Neldner B, Gui J, Craig RW, Suresh M. Mcl-1 regulates effector and memory CD8 T-cell differentiation during acute viral infection. Virology. 2016;490:75\u201382.","journal-title":"Virology"},{"key":"1820_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2719","volume":"4","author":"P Koenen","year":"2013","unstructured":"Koenen P, Heinzel S, Carrington EM, Happo L, Alexander WS, Zhang J-G, et al. Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals. Nat Commun. 2013;4:1735.","journal-title":"Nat Commun"},{"key":"1820_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/icb.2017.72","volume":"95","author":"EM Carrington","year":"2017","unstructured":"Carrington EM, Tarlinton DM, Gray DH, Huntington ND, Zhan Y, Lew AM. The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules. Immunol Cell Biol. 2017;95:870\u20137.","journal-title":"Immunol Cell Biol"},{"key":"1820_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"1820_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Toumelin-Braizat GL, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature"},{"key":"1820_CR21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","volume":"132","author":"MS Brennan","year":"2018","unstructured":"Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, et al. Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 2018;132:1573\u201383.","journal-title":"Blood"},{"key":"1820_CR22","unstructured":"ADIR. Phase I study of S64315 administred intravenously in patients with acute myeloid leukaemia or myelodysplastic syndrome. NCT02979366. https:\/\/clinicaltrials.gov\/study\/NCT02979366."},{"key":"1820_CR23","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s43018-024-00814-0","volume":"5","author":"U Rauh","year":"2024","unstructured":"Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024;5:1479\u201393.","journal-title":"Nat Cancer"},{"key":"1820_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ni.2649","volume":"14","author":"W Pierson","year":"2013","unstructured":"Pierson W, Cauwe B, Policheni A, Schlenner SM, Franckaert D, Berges J, et al. Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells. Nat Immunol. 2013;14:959\u201365.","journal-title":"Nat Immunol"},{"key":"1820_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nri3605","volume":"14","author":"A Liston","year":"2014","unstructured":"Liston A, Gray DHD. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14:154\u201365.","journal-title":"Nat Rev Immunol"},{"key":"1820_CR26","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1038\/s41418-020-0585-1","volume":"27","author":"CE Teh","year":"2020","unstructured":"Teh CE, Robbins AK, Henstridge DC, Dewson G, Diepstraten ST, Kelly G, et al. MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3+ regulatory T cells. Cell Death Differ. 2020;27:3374\u201385.","journal-title":"Cell Death Differ"},{"key":"1820_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21573-x","volume":"12","author":"R Kolb","year":"2021","unstructured":"Kolb R, De U, Khan S, Luo Y, Kim M-C, Yu H, et al. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021;12:1281.","journal-title":"Nat Commun"},{"key":"1820_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ccell.2023.03.019","volume":"41","author":"CE Weeden","year":"2023","unstructured":"Weeden CE, Gayevskiy V, Marceaux C, Batey D, Tan T, Yokote K, et al. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell. 2023;41:837\u201352.e6.","journal-title":"Cancer Cell"},{"key":"1820_CR29","doi-asserted-by":"publisher","first-page":"e2000731","DOI":"10.1371\/journal.pbio.2000731","volume":"15","author":"CE Weeden","year":"2017","unstructured":"Weeden CE, Chen Y, Ma SB, Hu Y, Ramm G, Sutherland KD, et al. Lung basal stem cells rapidly repair DNA damage using the error-prone nonhomologous end-joining pathway. PLoS Biol. 2017;15:e2000731.","journal-title":"PLoS Biol"},{"key":"1820_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12164-y","volume":"10","author":"SA Best","year":"2019","unstructured":"Best SA, Ding S, Kersbergen A, Dong X, Song J-Y, Xie Y, et al. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat Commun. 2019;10:4190.","journal-title":"Nat Commun"},{"key":"1820_CR31","doi-asserted-by":"publisher","first-page":"18581","DOI":"10.1073\/pnas.1003059107","volume":"107","author":"K Oboki","year":"2010","unstructured":"Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107:18581\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1820_CR32","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1084\/jem.20190993","volume":"216","author":"S Hemmers","year":"2019","unstructured":"Hemmers S, Schizas M, Azizi E, Dikiy S, Zhong Y, Feng Y, et al. IL-2 production by self-reactive CD4 thymocytes scales regulatory T cell generation in the thymus. J Exp Med. 2019;216:2466\u201378.","journal-title":"J Exp Med"},{"key":"1820_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"1820_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"1820_CR35","doi-asserted-by":"publisher","unstructured":"Schmidt U, Weigert M, Broaddus C, Myers G. Cell Detection with Star-Convex Polygons. In editors Frangi, A., Schnabel, J., Davatzikos, C., Alberola-L\u00f3pez, C., Fichtinger, G. Medical Image Computing and Computer AssistedIntervention \u2013 MICCAI 2018, Lecture Notes in Computer Science, Springer Nature. vol. 11071. 2018. https:\/\/doi.org\/10.1007\/978-3-030-00934-2_30","DOI":"10.1007\/978-3-030-00934-2_30"},{"key":"1820_CR36","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/cdd.2017.30","volume":"24","author":"EM Carrington","year":"2017","unstructured":"Carrington EM, Zhan Y, Brady JL, Zhang J-G, Sutherland RM, Anstee NS, et al. Anti-apoptotic proteins BCL-2, MCL-1, and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death Differ. 2017;24:878\u201388.","journal-title":"Cell Death Differ"},{"key":"1820_CR37","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1016\/j.celrep.2019.10.120","volume":"29","author":"A Li","year":"2019","unstructured":"Li A, Herbst RH, Canner D, Schenkel JM, Smith OC, Kim JY, et al. IL-33 signaling alters regulatory T cell diversity in support of tumor development. Cell Rep. 2019;29:2998\u20133008.e8.","journal-title":"Cell Rep"},{"key":"1820_CR38","doi-asserted-by":"publisher","first-page":"E10672","DOI":"10.1073\/pnas.1810580115","volume":"115","author":"AM Magnuson","year":"2018","unstructured":"Magnuson AM, Kiner E, Ergun A, Park JS, Asinovski N, Ortiz-Lopez A, et al. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. Proc Natl Acad Sci USA. 2018;115:E10672\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1820_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"1820_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaut.2011.12.008","volume":"38","author":"D Tischner","year":"2012","unstructured":"Tischner D, Gaggl I, Peschel I, Kaufmann M, Tuzlak S, Drach M, et al. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice. J Autoimmun. 2012;38:59\u201369.","journal-title":"J Autoimmun"},{"key":"1820_CR41","doi-asserted-by":"publisher","first-page":"10967","DOI":"10.1073\/pnas.1005256107","volume":"107","author":"EM Carrington","year":"2010","unstructured":"Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA. 2010;107:10967\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1820_CR42","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1182\/blood.2024024341","volume":"144","author":"M-X Luo","year":"2024","unstructured":"Luo M-X, Tan T, Trussart M, Poch A, Nguyen TMH, Speed TP, et al. Venetoclax dose escalation rapidly activates a BAFF\/BCL-2 survival axis in chronic lymphocytic leukemia. Blood. 2024;144:2748\u201361.","journal-title":"Blood"},{"key":"1820_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07544-w","volume":"16","author":"Y Pan","year":"2025","unstructured":"Pan Y, Zhou H, Sun Z, Zhu Y, Zhang Z, Han J, et al. Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application. Cell Death Dis. 2025;16:277.","journal-title":"Cell Death Dis"},{"key":"1820_CR44","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1097\/CM9.0000000000003450","volume":"137","author":"T Huang","year":"2024","unstructured":"Huang T, Li F, Wang Y, Gu J, Lu L. Tumor-infiltrating regulatory T cell: a promising therapeutic target in tumor microenvironment. Chin Me\u0301d J. 2024;137:2996\u20133009.","journal-title":"Chin Me\u0301d J"},{"key":"1820_CR45","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali DAA. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022;8:944\u201361.","journal-title":"Trends Cancer"},{"key":"1820_CR46","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s12276-023-01080-3","volume":"55","author":"J Yang","year":"2023","unstructured":"Yang J, Bae H. Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment. Exp Mol Med. 2023;55:1996\u20132004.","journal-title":"Exp Mol Med"},{"key":"1820_CR47","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2010.06.005","volume":"32","author":"FM Wensveen","year":"2010","unstructured":"Wensveen FM, van Gisbergen KPJM, Derks IAM, Gerlach C, Schumacher TN, van Lier RAW, et al. Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. Immunity. 2010;32:754\u201365.","journal-title":"Immunity"},{"key":"1820_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4049\/jimmunol.181.1.521","volume":"181","author":"I Dzhagalov","year":"2008","unstructured":"Dzhagalov I, Dunkle A, He Y-W. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J Immunol. 2008;181:521\u20138.","journal-title":"J Immunol"},{"key":"1820_CR49","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3389\/fimmu.2017.01809","volume":"8","author":"Y Zhan","year":"2017","unstructured":"Zhan Y, Carrington EM, Zhang Y, Heinzel S, Lew AM. Life and death of activated T cells: how are they different from na\u00efve T cells? Front Immunol. 2017;8:1809.","journal-title":"Front Immunol"},{"key":"1820_CR50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cei.12804","volume":"185","author":"AL Rodr\u00edguez-Perea","year":"2016","unstructured":"Rodr\u00edguez-Perea AL, Arcia ED, Rueda CM, Velilla PA. Phenotypical characterization of regulatory T cells in humans and rodents. Clin Exp Immunol. 2016;185:281\u201391.","journal-title":"Clin Exp Immunol"},{"key":"1820_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1146\/annurev-immunol-032712-095948","volume":"34","author":"M Panduro","year":"2016","unstructured":"Panduro M, Benoist C, Mathis D. Tissue Tregs. Annu Rev Immunol. 2016;34:609\u201333.","journal-title":"Annu Rev Immunol"},{"key":"1820_CR52","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41385-019-0176-y","volume":"12","author":"E Pastille","year":"2019","unstructured":"Pastille E, Wasmer M-H, Adamczyk A, Vu VP, Mager LF, Phuong NNT, et al. The IL-33\/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. Mucosal Immunol. 2019;12:990\u20131003.","journal-title":"Mucosal Immunol"},{"key":"1820_CR53","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature13577","volume":"513","author":"C Schiering","year":"2014","unstructured":"Schiering C, Krausgruber T, Chomka A, Fr\u00f6hlich A, Adelmann K, Wohlfert EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564\u20138.","journal-title":"Nature"},{"key":"1820_CR54","doi-asserted-by":"publisher","first-page":"e1527497","DOI":"10.1080\/2162402X.2018.1527497","volume":"8","author":"EC Halvorsen","year":"2019","unstructured":"Halvorsen EC, Franks SE, Wadsworth BJ, Harbourne BT, Cederberg RA, Steer CA, et al. IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner. OncoImmunology. 2019;8:e1527497.","journal-title":"OncoImmunology"},{"key":"1820_CR55","doi-asserted-by":"publisher","first-page":"12471","DOI":"10.3390\/ijms232012471","volume":"23","author":"U Sumarni","year":"2022","unstructured":"Sumarni U, Zhu J, Sinnberg T, Eberle J. Sensitivity of cutaneous T-cell lymphoma cells to the Mcl-1 inhibitor S63845 correlates with the lack of Bcl-w expression. Int J Mol Sci. 2022;23:12471.","journal-title":"Int J Mol Sci"},{"key":"1820_CR56","doi-asserted-by":"publisher","first-page":"e000860","DOI":"10.1136\/jitc-2020-000860","volume":"8","author":"F Zammarchi","year":"2020","unstructured":"Zammarchi F, Havenith K, Bertelli F, Vijayakrishnan B, Chivers S, Berkel PH, et al. CD25-targeted antibody\u2013drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020;8:e000860.","journal-title":"J Immunother Cancer"},{"key":"1820_CR57","unstructured":"LeBruchec Y A. Phase 1b, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of camidanlumab tesirine (ADCT-301) as monotherapy or in combination in patients with selected advanced solid tumors. 2024. https:\/\/clinicaltrials.gov\/study\/NCT03621982."},{"key":"1820_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly KA, Kuchroo M, Venkat A, Khatun A, Wang J, William I, et al. A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing anti-tumor immune response. Sci Immunol. 2021;6:eabg7836.","journal-title":"Sci Immunol"},{"key":"1820_CR59","first-page":"499","volume":"21","author":"Z Fang","year":"2024","unstructured":"Fang Z, Ding X, Huang H, Jiang H, Jiang J, Zheng X. Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells. Cancer Biol Med. 2024;21:499\u2013512.","journal-title":"Cancer Biol Med"},{"key":"1820_CR60","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan S-L, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity. 2021;54:2338\u201353.e6.","journal-title":"Immunity"},{"key":"1820_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1817","volume":"14","author":"L Ni","year":"2024","unstructured":"Ni L. Potential mechanisms of cancer stem-like progenitor T-cell bio-behaviours. Clin Transl Med. 2024;14:e1817.","journal-title":"Clin Transl Med"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01820-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01820-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01820-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:03:19Z","timestamp":1784120599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01820-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":61,"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01820-8","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with recognised ethical guidelines (Declaration of Helsinki). Written informed consent was obtained from all lung and colorectal cancer patients by the Victorian Cancer Biobank prior to inclusion in the study, in accordance with protocols approved by the WEHI Institutional Review Board (HREC, approval #10\/04). Healthy PBMC used as a reference control was collected from a patient through the Victorian Blood Donor Registry (WEHI HREC approval #2016.066; Melbourne Health HREC\/16\/MH\/62).","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}